Renerve (ASX: RNV) said that a recent comparative study showed that patients undergoing peripheral nerve surgery who used its NervAlign nerve cuff saw a major decrease in post-surgery pain compared to patients who did not use the nerve cuff, according to a Friday Australian bourse filing.
Patients who were treated with the nerve cuff were more likely to indicate they would have their procedure again.
The nerve cuff is designed to protect repaired and regenerating nerves during the healing process after peripheral nerve injuries or repair surgery, per the filing.
Its shares surged over 31% on market close on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。